[go: up one dir, main page]

WO2009044918A1 - ニューロメジンｕ誘導体 - Google Patents

ニューロメジンｕ誘導体 Download PDF

Info

Publication number
WO2009044918A1
WO2009044918A1 PCT/JP2008/068185 JP2008068185W WO2009044918A1 WO 2009044918 A1 WO2009044918 A1 WO 2009044918A1 JP 2008068185 W JP2008068185 W JP 2008068185W WO 2009044918 A1 WO2009044918 A1 WO 2009044918A1
Authority
WO
WIPO (PCT)
Prior art keywords
neuromedin
derivative
acid sequence
intended
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/068185
Other languages
English (en)
French (fr)
Inventor
Tetsuya Ohtaki
Yasushi Masuda
Satoshi Kumano
Hiroshi Inooka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to CA2701612A priority Critical patent/CA2701612A1/en
Priority to US12/681,747 priority patent/US20100286035A1/en
Priority to JP2009536136A priority patent/JPWO2009044918A1/ja
Priority to EP08836074A priority patent/EP2206721A1/en
Publication of WO2009044918A1 publication Critical patent/WO2009044918A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

　本発明は、新規摂食抑制剤を提供することを、目的とする。 　本発明はまた、末梢投与等の通常の投与形態でも、高い摂食抑制作用を表すＮＭＵ誘導体を提供することを、目的とする。 　ニューロメジンＵのアミノ配列のＣ末端の少なくとも８アミノ酸を含み、かつニューロメジンＵのアミノ酸配列と同一または実質的に同一のアミノ酸配列、からなるポリペプチドに、 特定の構造を有するリンカーを介して、メトキシポリエチレングリコールが結合しているニューロメジンＵ誘導体。
PCT/JP2008/068185 2007-10-05 2008-10-06 ニューロメジンｕ誘導体 Ceased WO2009044918A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA2701612A CA2701612A1 (en) 2007-10-05 2008-10-06 Neuromedin u derivative
US12/681,747 US20100286035A1 (en) 2007-10-05 2008-10-06 Neuromedin u derivative
JP2009536136A JPWO2009044918A1 (ja) 2007-10-05 2008-10-06 ニューロメジンｕ誘導体
EP08836074A EP2206721A1 (en) 2007-10-05 2008-10-06 Neuromedin u derivative

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-261847 2007-10-05
JP2007261847 2007-10-05

Publications (1)

Publication Number Publication Date
WO2009044918A1 true WO2009044918A1 (ja) 2009-04-09

Family

ID=40526330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/068185 Ceased WO2009044918A1 (ja) 2007-10-05 2008-10-06 ニューロメジンｕ誘導体

Country Status (5)

Country Link
US (1) US20100286035A1 (ja)
EP (1) EP2206721A1 (ja)
JP (1) JPWO2009044918A1 (ja)
CA (1) CA2701612A1 (ja)
WO (1) WO2009044918A1 (ja)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010116752A1 (ja) * 2009-04-08 2010-10-14 武田薬品工業株式会社 ニューロメジンｕ誘導体
WO2012050227A1 (en) 2010-10-13 2012-04-19 Takeda Pharmaceutical Company Limited Peptide derivative
WO2017047788A1 (ja) * 2015-09-18 2017-03-23 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
WO2018109540A1 (en) 2016-12-13 2018-06-21 Instituto De Medicina Molecular Methods of treating diseases associated with ilc2 cells
JP2019530678A (ja) * 2016-09-18 2019-10-24 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｙａｐ１のｏｃｔ４との相互作用を標的とするｙａｐ１阻害剤
JP2020506223A (ja) * 2017-01-13 2020-02-27 ヴァゾミューン セラピューティクス インコーポレイテッド 血管新生を促進する薬剤ならびにその方法および使用
US11685725B2 (en) 2018-03-14 2023-06-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. YAP1 inhibitors that target the interaction of YAP1 with OCT4
WO2024149820A1 (en) 2023-01-12 2024-07-18 Boehringer Ingelheim International Gmbh Nmu receptor 2 agonists
RU2825663C2 (ru) * 2015-09-18 2024-08-28 Юниверсити Оф Миязаки Длительно действующее производное адреномедуллина
WO2026013210A1 (en) 2024-07-11 2026-01-15 Boehringer Ingelheim International Gmbh Novel nmu receptor 2 agonists

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241051A1 (en) 2002-12-26 2006-10-26 Chieko Kitada Metastin derivatives and use thereof
JP4346650B2 (ja) * 2004-06-25 2009-10-21 武田薬品工業株式会社 メタスチン誘導体およびその用途
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090093615A1 (en) * 2005-12-22 2009-04-09 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
US20090099334A1 (en) * 2005-12-22 2009-04-16 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
US20110118172A1 (en) * 2008-04-24 2011-05-19 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
SI2314609T1 (sl) * 2008-07-30 2017-05-31 Takeda Pharmaceutical Company Limited Derivat metastina in njegova uporaba
WO2013075117A2 (en) * 2011-11-17 2013-05-23 John Wahren Pegylated c-peptide
AR097661A1 (es) 2013-09-17 2016-04-06 Obi Pharma Inc Composiciones de una vacuna de carbohidratos para inducir respuestas inmunológicas y sus usos en el tratamiento del cáncer
US10155798B2 (en) 2013-12-20 2018-12-18 The Regents Of The University Of California Anti-obesity compounds derived from neuromedin U
HK1256912A1 (zh) 2015-09-04 2019-10-04 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
US10501341B2 (en) 2015-12-04 2019-12-10 King Fahd University Of Petroleum And Minerals Method for removing heavy metals from wastewater
US10364164B2 (en) 2015-12-04 2019-07-30 King Fahd University Of Petroleum And Minerals Cross-linked polymeric resin and methods for wastewater treatment
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI780045B (zh) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
RU2018140976A (ru) 2016-04-22 2020-05-22 Оби Фарма, Инк. Иммунотерапия рака путем иммунной активации или иммунной модуляции через антигены серии globo
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
KR20190077103A (ko) 2016-11-21 2019-07-02 오비아이 파머 인코퍼레이티드 접합된 생물학적 분자, 제약 조성물 및 방법
US12161694B2 (en) 2017-03-24 2024-12-10 The Broad Institute, Inc. Methods and compositions for regulating innate lymphoid cell inflammatory responses
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109135A2 (en) * 2006-03-20 2007-09-27 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69929311T2 (de) * 1998-03-24 2006-09-07 Nof Corp. Oximanderivate und verfahren zu ihrer herstellung
JP4123856B2 (ja) * 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007109135A2 (en) * 2006-03-20 2007-09-27 Merck & Co., Inc. Neuromedin u receptor agonists and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HASHIMOTO T. ET AL.: "Structure-activity relationships of neuromedin U. II. Highly potent analogs substituted or modified at the N-terminus of neuromedin U-8.", CHEM PHARM BULL(TOKYO), vol. 43, no. 7, 1995, pages 1154 - 1157 *
PASUT G. ET AL.: "PEGylation of Proteins as Tailored Chemistry for Optimized Bioconjugates.", ADVANCES IN POLYMER SCIENCE, vol. 192, 2006, pages 95 - 134, XP001525562 *
SAKURA N. ET AL.: "Structure-activity relationships of neuromedin U.I. Contractile activity of dog neuromedin U-related peptides on isolated chicken crop smooth muscle.", CHEM PHARM BULL(TOKYO), vol. 43, no. 7, 1995, pages 1148 - 1153, XP008132875 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010116752A1 (ja) * 2009-04-08 2010-10-14 武田薬品工業株式会社 ニューロメジンｕ誘導体
CN102459311A (zh) * 2009-04-08 2012-05-16 武田药品工业株式会社 神经调节肽u衍生物
JPWO2010116752A1 (ja) * 2009-04-08 2012-10-18 武田薬品工業株式会社 ニューロメジンｕ誘導体
CN102459311B (zh) * 2009-04-08 2015-08-19 武田药品工业株式会社 神经调节肽u衍生物
US9175037B2 (en) 2009-04-08 2015-11-03 Takeda Pharmaceutical Company Limited Neuromedin U derivative
WO2012050227A1 (en) 2010-10-13 2012-04-19 Takeda Pharmaceutical Company Limited Peptide derivative
US11478551B2 (en) 2015-09-18 2022-10-25 University Of Miyazaki Long-acting adrenomedullin derivative
WO2017047788A1 (ja) * 2015-09-18 2017-03-23 国立大学法人宮崎大学 長時間作用型アドレノメデュリン誘導体
JPWO2017047788A1 (ja) * 2015-09-18 2018-07-05 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
US12171836B2 (en) 2015-09-18 2024-12-24 University Of Miyazaki Long-acting adrenomedullin derivative
RU2825663C2 (ru) * 2015-09-18 2024-08-28 Юниверсити Оф Миязаки Длительно действующее производное адреномедуллина
US10842879B2 (en) 2015-09-18 2020-11-24 University Of Miyazaki Long-acting adrenomedullin derivative
RU2738416C2 (ru) * 2015-09-18 2020-12-14 Юниверсити Оф Миязаки Длительно действующее производное адреномедуллина
JP6991569B2 (ja) 2015-09-18 2022-02-15 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
US11530182B2 (en) 2016-09-18 2022-12-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. YAP1 inhibitors that target the interaction of YAP1 with Oct4
US11999695B2 (en) 2016-09-18 2024-06-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. YAP1 inhibitors that target the interaction of YAP1 with OCT4
JP2019530678A (ja) * 2016-09-18 2019-10-24 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド Ｙａｐ１のｏｃｔ４との相互作用を標的とするｙａｐ１阻害剤
WO2018109540A1 (en) 2016-12-13 2018-06-21 Instituto De Medicina Molecular Methods of treating diseases associated with ilc2 cells
JP7107968B2 (ja) 2017-01-13 2022-07-27 ヴァゾミューン セラピューティクス インコーポレイテッド 血管新生を促進する薬剤ならびにその方法および使用
JP2020506223A (ja) * 2017-01-13 2020-02-27 ヴァゾミューン セラピューティクス インコーポレイテッド 血管新生を促進する薬剤ならびにその方法および使用
US11685725B2 (en) 2018-03-14 2023-06-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. YAP1 inhibitors that target the interaction of YAP1 with OCT4
WO2024149820A1 (en) 2023-01-12 2024-07-18 Boehringer Ingelheim International Gmbh Nmu receptor 2 agonists
WO2026013210A1 (en) 2024-07-11 2026-01-15 Boehringer Ingelheim International Gmbh Novel nmu receptor 2 agonists

Also Published As

Publication number Publication date
US20100286035A1 (en) 2010-11-11
CA2701612A1 (en) 2009-04-09
JPWO2009044918A1 (ja) 2011-02-17
EP2206721A1 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
WO2009044918A1 (ja) ニューロメジンｕ誘導体
BRPI0620806B8 (pt) complexo e composição compreendendo um peptídeo e uma molécula carga, e uso da referida composição
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
EP2251018A3 (en) Stable amorphous calcium carbonate comprising phosphorylated amino acids, synthetic phosphorylated peptides, and gastrolith proteins
WO2008039483A3 (en) Modified self-assembling peptides
EP2455462A3 (en) Lipase variants for pharmaceutical use
EP3372617A3 (en) Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
WO2008052173A3 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
EP2251348A3 (en) Peptides and their use
NZ591261A (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
WO2008028977A3 (en) Serum albumin binding proteins with long half-lives
WO2006111524A3 (en) Il-21 variants
WO2008049920A3 (en) Il-21 variants
NZ598159A (en) Transport molecules using reverse sequence hiv-tat polypeptides
WO2008093058A3 (en) Peptides and their use
WO2008064910A3 (en) Metastasis-specific peptides and their diagnostic and therapeutic applications
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
EP2481748A3 (en) Foxp3 peptide vaccine
EP3026057A3 (en) Compositions for prevention and treatment of neurodegenerative diseases
WO2010062570A3 (en) COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE
WO2007110772A8 (en) Immunomodulating oligopeptides
TH127804A (th) องค์ประกอบและวิธีที่ประกอบรวมด้วยเบสิค อะมิโน แอซิด เพพไทด์ และโพรทิเอส

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08836074

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009536136

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2701612

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008836074

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12681747

Country of ref document: US